Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account

Table of contents

DetailsRelated

Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium

FDA-2026-P-6737-0007Supporting & Related Material
Document

Details

The document's own metadata, straight from the source system.

Title
Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium
Posted
Jun 15, 2026
Agency
Food and Drug Administration (FDA)
Topics
View on regulations.gov ↗